glutathione and sacoidosis Drug-induced comorbidities in patients with sarcoidosis glutathione and sacoidosis Pulmonary Sarcoidosis:

Human trials showed that in people with high-risk features, treatment with minocycline reduced in 6 months the risk of conversion to MS, decreased lesion volume, and showed the absence of new enhancing lesions, but this effect did not last beyond 24 months of study (Preiningerova et al., 2022)

Computational Staining of Pathology Images to Study the Tumor Microenvironment in Lung Cancer

2025;32(1):e101185 Ramos Garcia V

Retatrutide is an investigational peptide drug developed by Eli Lilly that acts as a triple agonist, simultaneously targeting three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors

Neuroinflammation 10, 815